Correlation Engine 2.0
Clear Search sequence regions

  • guidelines (6)
  • humans (1)
  • renal function (5)
  • understand (1)
  • vancomycin (11)
  • weight (6)
  • Sizes of these terms reflect their relevance to your search.

    Vancomycin dosing decisions are informed by factors such as body weight and renal function. It is important to understand the impact of obesity on vancomycin pharmacokinetics and how this may influence dosing decisions. Vancomycin dosing guidelines use varied descriptors of body weight and renal function. There is uncertainty whether current dosing guidelines result in attainment of therapeutic targets in obese individuals. Literature was explored using PubMed, Embase, and Google Scholar for articles from January 1980 to July 2021 regarding obesity-driven physiological changes, their influence on vancomycin pharmacokinetics and body size descriptors and renal function calculations in vancomycin dosing. Pharmacokinetic simulations reflective of international vancomycin dosing guidelines were conducted to evaluate the ability of using total, ideal, and adjusted body weight, as well as Cockcroft-Gault and CKD-EPI equations to attain an area-under-the-curve to minimum inhibitory concentration ratio (AUC24/MIC) target (400-650) in obese individuals. Vancomycin pharmacokinetics in obese individuals remains debated. Guidelines that determine loading doses using total body weight, and maintenance doses adjusted based on renal function and adjusted body weight, may be most appropriate for obese individuals. Use of ideal body weight leads to subtherapeutic vancomycin exposure and underestimation of renal function.


    Sherilyn Wong, Stephanie E Reuter, Graham Rd Jones, Sophie L Stocker. Review and evaluation of vancomycin dosing guidelines for obese individuals. Expert opinion on drug metabolism & toxicology. 2022 May;18(5):323-335

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35815356

    View Full Text